ARTICLE | Clinical News
Cinryze regulatory update
December 20, 2016 12:50 AM UTC
EMA’s CHMP recommended expanding the label of Cinryze from Shire for treatment and pre-procedure prevention of angioedema attacks to include children ages 2-11 with hereditary angioedema (HAE); and fo...
BCIQ Company Profiles
BCIQ Target Profiles